Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

TPST | Tempest Therapeutics, Inc.

Index- P/E- EPS (ttm)-2.41 Insider Own3.00% Shs Outstand14.10M Perf Week-20.50%
Market Cap5.24M Forward P/E- EPS next Y-1.60 Insider Trans0.00% Shs Float12.67M Perf Month-37.57%
Income-33.30M PEG- EPS next Q-0.57 Inst Own71.30% Short Float / Ratio0.26% / 0.25 Perf Quarter-67.75%
Sales- P/S- EPS this Y58.60% Inst Trans-0.34% Short Interest0.03M Perf Half Y-72.36%
Book/sh0.36 P/B1.07 EPS next Y21.60% ROA-75.00% Target Price15.67 Perf Year-81.12%
Cash/sh1.30 P/C0.30 EPS next 5Y- ROE-218.60% 52W Range0.39 - 4.21 Perf YTD-66.35%
Dividend- P/FCF- EPS past 5Y60.50% ROI- 52W High-90.82% Beta0.90
Dividend %- Quick Ratio2.10 Sales past 5Y- Gross Margin- 52W Low-0.77% ATR0.06
Employees19 Current Ratio2.10 Sales Q/Q- Oper. Margin- RSI (14)29.03 Volatility9.07% 11.07%
OptionableNo Debt/Eq2.10 EPS Q/Q32.10% Profit Margin- Rel Volume1.57 Prev Close0.48
ShortableYes LT Debt/Eq1.50 EarningsAug 10 AMC Payout- Avg Volume132.00K Price0.39
Recom1.50 SMA20-25.65% SMA50-46.42% SMA200-73.81% Volume207,412 Change-19.12%
Sep-19-23 08:00AM
Sep-05-23 08:00AM
Aug-10-23 04:13PM
Jul-19-23 08:00AM
May-31-23 04:05PM
05:00PM Loading…
May-25-23 05:00PM
May-19-23 04:05PM
May-10-23 04:15PM
Apr-28-23 08:00AM
Apr-27-23 04:58PM
Apr-26-23 06:41PM
Apr-17-23 09:00AM
Mar-22-23 05:26PM
Mar-15-23 04:05PM
Mar-14-23 04:30PM
04:05PM Loading…
Nov-22-22 04:05PM
Nov-10-22 09:00AM
Nov-08-22 08:00AM
Nov-02-22 08:00AM
Oct-06-22 08:00AM
Sep-07-22 08:00AM
Aug-15-22 08:00AM
Jul-07-22 08:00AM
Jun-09-22 08:00AM
Jun-06-22 04:05PM
May-26-22 04:57PM
May-13-22 08:00AM
Apr-27-22 10:01AM
Apr-08-22 01:00PM
04:00PM Loading…
Mar-29-22 04:00PM
Mar-10-22 08:00AM
Mar-08-22 04:30PM
Feb-09-22 08:00AM
Nov-18-21 08:00AM
Nov-12-21 07:00AM
Nov-10-21 04:05PM
Nov-09-21 08:00AM
Nov-08-21 08:00AM
Oct-01-21 08:00AM
Sep-20-21 08:00AM
Sep-13-21 08:00AM
Sep-09-21 04:01PM
Aug-12-21 04:01PM
Aug-09-21 08:00AM
Jul-09-21 08:00AM
Jul-01-21 04:00PM
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.